Freestone Grove Partners LP Invests $15.48 Million in Edwards Lifesciences Corporation $EW

Key Points

• Freestone Grove Partners acquired 171,081 Edwards Lifesciences shares worth approximately $15.48 million in the second quarter. Institutional investors collectively own 79.46% of the company.
• Analysts maintain a favorable outlook, with 17 Buy ratings and six Holds producing a “Moderate Buy” consensus and an average price target of $100.27.
• Edwards exceeded quarterly expectations, reporting adjusted EPS of $0.78 versus $0.74 expected and revenue of $1.74 billion, up 13.6% year over year; full-year 2026 EPS guidance is $2.95–$3.05.

Freestone Grove Partners LP purchased a new stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 171,081 shares of the medical research company's stock, valued at approximately $15,476,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC acquired a new stake in Edwards Lifesciences during the 4th quarter worth about $266,000. NewEdge Advisors LLC grew its stake in Edwards Lifesciences by 8.1% during the 2nd quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company's stock valued at $2,787,000 after acquiring an additional 2,665 shares in the last quarter. Sei Investments Co. increased its holdings in shares of Edwards Lifesciences by 16.7% in the 2nd quarter. Sei Investments Co. now owns 412,808 shares of the medical research company's stock valued at $32,285,000 after purchasing an additional 58,988 shares during the period. Squarepoint Ops LLC lifted its position in shares of Edwards Lifesciences by 277.7% in the second quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company's stock worth $5,417,000 after purchasing an additional 50,924 shares in the last quarter. Finally, Treasurer of the State of North Carolina lifted its position in shares of Edwards Lifesciences by 0.4% in the second quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company's stock worth $21,028,000 after purchasing an additional 1,065 shares in the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, VP Daniel J. Lippis sold 619 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the sale, the vice president owned 40,034 shares in the company, valued at approximately $3,684,329.02. This trade represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 1,857 shares of company stock worth $170,305. Insiders own 0.31% of the company's stock.

Wall Street Analysts Forecast Growth

EW has been the topic of several research reports. Leerink Partners upgraded shares of Edwards Lifesciences from a "market perform" rating to an "outperform" rating and upped their price objective for the company from $87.00 to $101.00 in a research note on Friday, July 24th. TD Cowen reissued a "buy" rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. UBS Group assumed coverage on shares of Edwards Lifesciences in a research note on Tuesday, July 28th. They issued a "buy" rating and a $110.00 price target on the stock. JPMorgan Chase & Co. increased their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "overweight" rating in a report on Friday, July 24th. Finally, Piper Sandler reissued an "overweight" rating and set a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a research report on Friday, July 24th. Seventeen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $100.27.

Edwards Lifesciences Stock Performance

Shares of NYSE EW opened at $89.97 on Friday. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29. The company has a market cap of $51.81 billion, a P/E ratio of 51.71, a P/E/G ratio of 2.38 and a beta of 0.85. The business's 50 day moving average is $89.48 and its two-hundred day moving average is $84.99. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company had revenue of $1.74 billion during the quarter, compared to analysts' expectations of $1.70 billion. During the same period in the prior year, the business earned $0.67 earnings per share. Edwards Lifesciences's revenue for the quarter was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, equities analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source